Annual FCF:
-$434.18M+$87.39M(+16.76%)Summary
- As of today, RARE annual free cash flow is -$434.18 million, with the most recent change of +$87.39 million (+16.76%) on December 31, 2024.
- During the last 3 years, RARE annual free cash flow has fallen by -$22.39 million (-5.44%).
- RARE annual free cash flow is now -6712.79% below its all-time high of -$6.37 million, reached on December 31, 2011.
Performance
RARE Free Cash Flow Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Quarterly FCF:
-$110.73M+$72.07M(+39.42%)Summary
- As of today, RARE quarterly free cash flow is -$110.73 million, with the most recent change of +$72.07 million (+39.42%) on June 30, 2025.
- Over the past year, RARE quarterly free cash flow has dropped by -$29.26 million (-35.92%).
- RARE quarterly free cash flow is now -232.98% below its all-time high of $83.27 million, reached on June 30, 2020.
Performance
RARE Quarterly Free Cash Flow Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
TTM FCF:
-$442.30M-$29.26M(-7.08%)Summary
- As of today, RARE TTM free cash flow is -$442.30 million, with the most recent change of -$29.26 million (-7.08%) on June 30, 2025.
- Over the past year, RARE TTM free cash flow has increased by +$50.18 million (+10.19%).
- RARE TTM free cash flow is now -12465.37% below its all-time high of -$3.52 million, reached on September 1, 2012.
Performance
RARE TTM Free Cash Flow Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Free Cash Flow Formula
FCF = Cash From Operations − CAPEX
RARE Free Cash Flow Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1Y1 Year | +16.8% | -35.9% | +10.2% |
| 3Y3 Years | -5.4% | -2.4% | -0.9% |
| 5Y5 Years | -17.3% | -233.0% | -149.1% |
RARE Free Cash Flow Highs & Lows
| PeriodPeriod | Annual vs HighAnnual vs High | Annual vs LowAnnual vs Low | Quarter. vs HighQuarter. vs High | Quarter. vs LowQuarter. vs Low | TTM vs HighTTM vs High | TTM vs LowTTM vs Low | |
|---|---|---|---|---|---|---|---|
| 3Y | 3-Year | -5.4% | +17.6% | -61.4% | +45.7% | -7.1% | +20.1% |
| 5Y | 5-Year | -146.5% | +17.6% | -62.8% | +45.7% | -151.1% | +20.1% |
| All-Time | All-Time | -6712.8% | +17.6% | -233.0% | +45.7% | >-9999.0% | +20.1% |
RARE Free Cash Flow History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2025 | - | -$110.73M(+39.4%) | -$442.30M(-7.1%) |
| Mar 2025 | - | -$182.80M(-128.1%) | -$413.04M(+4.9%) |
| Dec 2024 | -$434.18M(+16.8%) | -$80.16M(-16.8%) | -$434.18M(+1.2%) |
| Sep 2024 | - | -$68.61M(+15.8%) | -$439.53M(+10.8%) |
| Jun 2024 | - | -$81.47M(+60.1%) | -$492.48M(+9.4%) |
| Mar 2024 | - | -$203.94M(-138.5%) | -$543.61M(-4.2%) |
| Dec 2023 | -$521.57M(+1.0%) | -$85.50M(+29.7%) | -$521.57M(+5.7%) |
| Sep 2023 | - | -$121.57M(+8.3%) | -$553.38M(-0.0%) |
| Jun 2023 | - | -$132.60M(+27.1%) | -$553.20M(-4.6%) |
| Mar 2023 | - | -$181.90M(-55.1%) | -$528.78M(-0.4%) |
| Dec 2022 | -$526.59M(-27.9%) | -$117.31M(+3.4%) | -$526.59M(-9.8%) |
| Sep 2022 | - | -$121.39M(-12.2%) | -$479.67M(-9.4%) |
| Jun 2022 | - | -$108.18M(+39.8%) | -$438.49M(-5.5%) |
| Mar 2022 | - | -$179.71M(-155.3%) | -$415.73M(-1.0%) |
| Dec 2021 | -$411.79M(-133.8%) | -$70.39M(+12.2%) | -$411.79M(+2.8%) |
| Sep 2021 | - | -$80.21M(+6.1%) | -$423.52M(-3.0%) |
| Jun 2021 | - | -$85.43M(+51.4%) | -$411.33M(-69.5%) |
| Mar 2021 | - | -$175.76M(-114.0%) | -$242.64M(-37.8%) |
| Dec 2020 | -$176.13M(+52.4%) | -$82.12M(-20.7%) | -$176.13M(+0.8%) |
| Sep 2020 | - | -$68.02M(-181.7%) | -$177.54M(+12.6%) |
| Jun 2020 | - | $83.27M(+176.2%) | -$203.06M(+46.7%) |
| Mar 2020 | - | -$109.25M(-30.8%) | -$380.63M(-2.8%) |
| Dec 2019 | -$370.21M(-25.6%) | -$83.54M(+10.7%) | -$370.21M(-7.7%) |
| Sep 2019 | - | -$93.54M(+0.8%) | -$343.72M(-7.3%) |
| Jun 2019 | - | -$94.30M(+4.6%) | -$320.37M(-5.6%) |
| Mar 2019 | - | -$98.83M(-73.3%) | -$303.52M(-3.0%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2018 | -$294.64M(-14.8%) | -$57.05M(+18.7%) | -$294.64M(+8.0%) |
| Sep 2018 | - | -$70.19M(+9.4%) | -$320.32M(-2.3%) |
| Jun 2018 | - | -$77.45M(+13.9%) | -$313.16M(-9.9%) |
| Mar 2018 | - | -$89.95M(-8.7%) | -$284.90M(-11.0%) |
| Dec 2017 | -$256.64M(-49.9%) | -$82.72M(-31.3%) | -$256.64M(-15.5%) |
| Sep 2017 | - | -$63.03M(-28.1%) | -$222.26M(-16.4%) |
| Jun 2017 | - | -$49.20M(+20.2%) | -$190.98M(-2.4%) |
| Mar 2017 | - | -$61.69M(-27.6%) | -$186.48M(-8.9%) |
| Dec 2016 | -$171.16M(-54.3%) | -$48.35M(-52.3%) | -$171.16M(-3.6%) |
| Sep 2016 | - | -$31.75M(+29.0%) | -$165.18M(+0.5%) |
| Jun 2016 | - | -$44.70M(+3.6%) | -$166.02M(-19.3%) |
| Mar 2016 | - | -$46.37M(-9.5%) | -$139.19M(-25.5%) |
| Dec 2015 | -$110.93M(-137.1%) | -$42.37M(-30.0%) | -$110.93M(-32.4%) |
| Sep 2015 | - | -$32.58M(-82.3%) | -$83.76M(-33.7%) |
| Jun 2015 | - | -$17.87M(+1.4%) | -$62.65M(-11.9%) |
| Mar 2015 | - | -$18.12M(-19.3%) | -$56.00M(-19.7%) |
| Dec 2014 | -$46.78M(-48.0%) | -$15.19M(-32.5%) | -$46.78M(-12.7%) |
| Sep 2014 | - | -$11.47M(-2.2%) | -$41.49M(-12.2%) |
| Jun 2014 | - | -$11.22M(-26.0%) | -$36.97M(-8.6%) |
| Mar 2014 | - | -$8.90M(+10.1%) | -$34.04M(-7.7%) |
| Dec 2013 | -$31.61M(-132.5%) | -$9.90M(-42.5%) | -$31.61M(-23.7%) |
| Sep 2013 | - | -$6.95M(+16.1%) | -$25.54M(-15.5%) |
| Jun 2013 | - | -$8.29M(-28.1%) | -$22.11M(-59.9%) |
| Mar 2013 | - | -$6.47M(-68.6%) | -$13.83M(-87.9%) |
| Dec 2012 | -$13.60M(-113.3%) | -$3.84M(-9.0%) | -$7.36M(-109.0%) |
| Sep 2012 | - | -$3.52M | -$3.52M |
| Dec 2011 | -$6.37M | - | - |
FAQ
- What is Ultragenyx Pharmaceutical Inc. annual free cash flow?
- What is the all-time high annual free cash flow for Ultragenyx Pharmaceutical Inc.?
- What is Ultragenyx Pharmaceutical Inc. annual free cash flow year-on-year change?
- What is Ultragenyx Pharmaceutical Inc. quarterly free cash flow?
- What is the all-time high quarterly free cash flow for Ultragenyx Pharmaceutical Inc.?
- What is Ultragenyx Pharmaceutical Inc. quarterly free cash flow year-on-year change?
- What is Ultragenyx Pharmaceutical Inc. TTM free cash flow?
- What is the all-time high TTM free cash flow for Ultragenyx Pharmaceutical Inc.?
- What is Ultragenyx Pharmaceutical Inc. TTM free cash flow year-on-year change?
What is Ultragenyx Pharmaceutical Inc. annual free cash flow?
The current annual free cash flow of RARE is -$434.18M
What is the all-time high annual free cash flow for Ultragenyx Pharmaceutical Inc.?
Ultragenyx Pharmaceutical Inc. all-time high annual free cash flow is -$6.37M
What is Ultragenyx Pharmaceutical Inc. annual free cash flow year-on-year change?
Over the past year, RARE annual free cash flow has changed by +$87.39M (+16.76%)
What is Ultragenyx Pharmaceutical Inc. quarterly free cash flow?
The current quarterly free cash flow of RARE is -$110.73M
What is the all-time high quarterly free cash flow for Ultragenyx Pharmaceutical Inc.?
Ultragenyx Pharmaceutical Inc. all-time high quarterly free cash flow is $83.27M
What is Ultragenyx Pharmaceutical Inc. quarterly free cash flow year-on-year change?
Over the past year, RARE quarterly free cash flow has changed by -$29.26M (-35.92%)
What is Ultragenyx Pharmaceutical Inc. TTM free cash flow?
The current TTM free cash flow of RARE is -$442.30M
What is the all-time high TTM free cash flow for Ultragenyx Pharmaceutical Inc.?
Ultragenyx Pharmaceutical Inc. all-time high TTM free cash flow is -$3.52M
What is Ultragenyx Pharmaceutical Inc. TTM free cash flow year-on-year change?
Over the past year, RARE TTM free cash flow has changed by +$50.18M (+10.19%)